In adults, a patient with a KIF5B–RET fusion–positive non–small cell lung cancer (NSCLC) and brain metastases showed a decrease in the intracranial disease burden upon treatment with vandetanib plus everolimus (33) as part of the phase I clinical trial in patients with advanced or metastatic cancer (NCT01582191). This evidence concerns the gene RET and non-small cell lung carcinoma.